Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Unternehmen & Branche
| Name | PROTHENA CORP PUBLIC LTD CO |
|---|---|
| Ticker | PRTA |
| CIK | 0001559053 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 618,0 Mio. USD |
| Beta | -0,33 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 9,684,000 | -244,092,000 | -4.53 | 326,804,000 | 280,474,000 |
| 2025-09-30 | 10-Q | 2,415,000 | -36,541,000 | -0.68 | 352,628,000 | 294,989,000 |
| 2025-06-30 | 10-Q | 4,420,000 | -125,767,000 | -2.34 | 399,066,000 | 324,331,000 |
| 2025-03-31 | 10-Q | 2,828,000 | -60,195,000 | -1.12 | 495,336,000 | 437,680,000 |
| 2024-12-31 | 10-K | 135,157,000 | -122,310,000 | -2.27 | 547,108,000 | 486,926,000 |
| 2024-09-30 | 10-Q | 970,000 | -59,001,000 | -1.10 | 595,254,000 | 534,362,000 |
| 2024-06-30 | 10-Q | 132,014,000 | 66,886,000 | 1.22 | 645,565,000 | 581,917,000 |
| 2024-03-31 | 10-Q | 50,000 | -72,239,000 | -1.34 | 623,194,000 | 502,399,000 |
| 2023-12-31 | 10-K | 91,370,000 | -147,028,000 | -2.76 | 696,382,000 | 561,365,000 |
| 2023-09-30 | 10-Q | 84,866,000 | 21,907,000 | 0.38 | 746,920,000 | 617,227,000 |
| 2023-06-30 | 10-Q | 4,019,000 | -54,595,000 | -1.03 | 720,649,000 | 581,679,000 |
| 2023-03-31 | 10-Q | 2,169,000 | -46,864,000 | -0.89 | 741,586,000 | 607,409,000 |
| 2022-12-31 | 10-K | 53,905,000 | -116,949,000 | -2.47 | 758,035,000 | 622,042,000 |
| 2022-09-30 | 10-Q | 1,517,000 | -45,764,000 | -0.97 | 554,440,000 | 404,648,000 |
| 2022-06-30 | 10-Q | 1,312,000 | -41,244,000 | -0.88 | 549,589,000 | 407,299,000 |
| 2022-03-31 | 10-Q | 1,153,000 | -36,290,000 | -0.78 | 581,412,000 | 438,887,000 |
| 2021-12-31 | 10-K | 200,577,000 | 66,975,000 | 1.38 | 609,366,000 | 466,042,000 |
| 2021-09-30 | 10-Q | 139,174,000 | 109,247,000 | 2.13 | 632,704,000 | 490,471,000 |
| 2021-06-30 | 10-Q | 60,071,000 | 27,642,000 | 0.58 | 436,378,000 | 288,207,000 |
| 2021-03-31 | 10-Q | 160,000 | -36,735,000 | -0.91 | 379,719,000 | 234,584,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-05-06 | EcoR1 Capital, LLC | 10% Owner | Open Market Sale | -1,984,053 | 7.64 | -15,164,712.29 | -89,5% | |
| 2025-05-05 | EcoR1 Capital, LLC | 10% Owner | Open Market Sale | -977,693 | 8.11 | -7,930,165.69 | -46,8% | |
| 2025-05-02 | EcoR1 Capital, LLC | 10% Owner | Open Market Sale | -3,317,938 | 8.36 | -27,744,929.35 | -163,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.